

Review Article

Consensus of Chinese Painologist Experts on Diagnosis and Treatment of Phantom Limb Pain

Yue Kan¹ , Jiang Zongbin^{2,*} , He Ruilin² , Xu Shengrong² , Zhou Zenghua²,
Feng Yi³ , Xiao Hong⁴ , Ma Ke⁵ , Li Shuiqing⁶ , Yang Liqiang⁷, Wang Yong⁸,
Sun Tao⁹ , Fan Xiaochong¹⁰, Xue Zhaoxia¹¹ , Feng Pengjiu¹², Zhang Daying¹³ ,
Fan Bifa^{14,*} 

¹Department of Pain Management, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

²Department of Painology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China

³Department of Painology, People Hospital of Peking University, Beijing, China

⁴Department of Pain Management, West China Hospital of Sichuan University, Chengdu, China

⁵Department of Painology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

⁶Department of Painology, Peking University Third Hospital, Beijing, China

⁷Department of Painology, Xuanwu Hospital Affiliated to Capital Medical University, Beijing, China

⁸Department of Pain Management, Aviation General Hospital of Chinese Medical University, Beijing, China

⁹Department of Painology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

¹⁰Department of Painology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

¹¹Department of Painology, The First Hospital of Shanxi Medical University, Taiyuan, China

¹²Department of Painology, Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, China

¹³Department of Painology, The First Affiliated Hospital of Nanchang University, Nanchang, China

¹⁴Department of Painology, China-Japan Friendship Hospital, Beijing, China

Abstract

Phantom limb pain (PLP), defined as neuropathic pain perceived in the missing portion of an amputated limb, represents a common and refractory condition significantly impairing patient rehabilitation and quality of life. Its pathogenesis is multifactorial, involving complex interactions between peripheral mechanisms (e.g., neuroma formation, ectopic discharges), central nervous system reorganization (including cortical remapping and spinal cord sensitization), and psychological components. Patients frequently present with heterogeneous pain descriptors, such as burning, shooting, or cramping sensations, which often coexist with residual limb pain, complicating clinical assessment. Despite the availability of diverse therapeutic interventions-ranging from pharmacotherapy (e.g., gabapentinoids, antidepressants, NMDA receptor antagonists) and physical modalities (e.g., transcranial magnetic stimulation, mirror therapy) to interventional procedures (e.g., nerve blocks, neuromodulation) and psychological approaches-treatment outcomes remain variable, and standardized clinical guidelines are lacking. This consensus, formulated by a panel of Chinese pain specialists, systematically reviews contemporary evidence on the

*Corresponding author: 2010pm@163.com (Jiang Zongbin), fbf1616@yeah.net (Fan Bifa)

Received: 9 October 2025; Accepted: 31 October 2025; Published: 11 December 2025



Copyright: © The Author(s), 2025. Published by Science Publishing Group. This is an **Open Access** article, distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

epidemiology, pathophysiology, diagnosis, and management of PLP. It aims to establish practical, evidence-based recommendations to guide the standardized diagnosis and stratified treatment of PLP, thereby optimizing therapeutic efficacy and improving functional outcomes for affected individuals.

Keywords

Phantom Limb Pain, Diagnosis, Treatment, Expert Consensus

1. Introduction

Phantom limb pain (PLP) refers to persistent nociceptive sensations perceived in the amputated portion of a limb [1]. After amputation, patients report phantom limb sensation (PLS), characterized by non-painful perceptions of the missing limb's position, shape, movement, temperature (cold or heat), or itching [2]. Additionally, many individuals report painful sensations such as burning, stabbing, throbbing, or electric shock-like pain, which is referred to as PLP [3]. Over 80% of amputees experience PLP, which significantly impairs residual limb function and rehabilitation [4]. It is estimated that by 2050, the amputee population in the United States will increase from 1.6 million in 2005 to 3.6 million [5]. The exact mechanisms underlying PLP remain unclear but likely involve peripheral, central, and psychological factors [2]. Due to its high incidence and therapeutic resistance, PLP represents a significant public health challenge. Over 25 treatment modalities exist, yet standardized protocols are lacking [6]. To address this gap, the Chinese Journal of Pain Medicine Editorial Board convened a multidisciplinary expert panel to establish the Chinese Expert Consensus on the Diagnosis and Treatment of PLP, aiming to standardize evidence-based clinical practices.

2. Epidemiology

The reported incidence of PLP ranges widely from 2% to 98% [7-9], with variations attributed to differences in study populations, amputation sites (upper or lower limb), study designs (prospective, retrospective, or cross-sectional), and assessment methods (interviews or questionnaires). Additional contributing factors include the lack of a standardized definition for PLP, and challenges in differentiating PLP from residual limb pain (RLP) and PLS [10].

Early studies reported PLP incidence rates of 72.4% at 8 days and 66.7% at 6 months post-amputation [11]. Nikolajsen et al. [12] reported PLP in 67% of amputees within the first week and 75% at 6 months. In a small mixed-etiology cohort (n=22), PLP incidence was 2.2% at 1 month post-amputation, whereas in non-traumatic amputees (n=52), it reached 82.7% at 12 months [13]. However, a 2010 study found a significantly lower PLP incidence (32%) at 6 months post-amputation [14]. This decline may be attributed to im-

proved understanding of PLP mechanisms, widespread adoption of preventive analgesia concepts, and enhanced perioperative pain management strategies [15].

3. Pathogenesis

The pathogenesis of PLP is complex, involving multiple mechanisms such as abnormal changes in the peripheral and central nervous systems, as well as psychological factors.

3.1. Peripheral Mechanisms

PLP is considered a type of neuropathic pain. Peripheral nerve injury caused by amputation can trigger an inflammatory response, releasing algogenic substances such as substance P, prostaglandins, bradykinin, and cytokines, which sensitize peripheral nociceptors and induce peripheral sensitization [16, 17]. Subsequent axonal regeneration and neuroma formation further sustain aberrant ectopic discharges, exacerbating peripheral sensitization [18]. Since cortical somatotopic maps retain pre-amputation sensory memories, residual peripheral nerve activity may be misinterpreted as originating from the missing limb, contributing to PLP [19, 20]. Research by Feng Aimin et al. [21] demonstrated that maintaining afferent input from the peripheral nerves at the residual limb through substitute stimulation can alleviate post-amputation RLP and mirror pain in the contralateral limb in rats. Furthermore, PLP has also been associated with sympathetic nervous system dysfunction [2].

3.2. Central Mechanisms

At the spinal cord level, PLP involves dorsal horn neurons sensitization, synaptic remodeling, and diminished spinal disinhibition [22]. At supraspinal levels, several hypotheses have been proposed to explain the mechanisms underlying PLP [23]:

3.2.1. Thalamic Modulation

Nociceptive signals project via the thalamus to cortical regions. After amputation, the thalamic nuclei representing the amputated region remain functionally active, and stimulation

of these nuclei can evoke PLS and PLP [24].

3.2.2. Cortical Reorganization

Adjacent cortical areas invade the amputated limb's sensorimotor representation, with fMRI studies confirming reorganization correlates with PLP severity and chronicity [25-27].

3.2.3. Pain Neuromatrix Dysfunction

The primary sensory cortex, anterior cingulate cortex, insula, amygdala, cerebellum, and limbic system together constitute the neural network matrix for pain perception [28], and its functional abnormalities can lead to PLP [29].

3.2.4. Proprioceptive Memory

Based on proprioceptive input theory, amputees may retain and recall the final pre-amputation proprioceptive input from the missing limb [30].

3.2.5. Neuroplasticity

Plastic changes in neurons and glial cells, affecting ion channels, protein receptors, neurotransmitters, and metabolic signaling pathways, constitute the molecular basis of PLP [31-34].

3.3. Psychological Mechanism

The profound psychological trauma and stress response induced by amputation lead to emotions such as fear, anxiety, and depression in patients, making psychological mechanisms a significant factor in PLP [35].

4. Clinical Manifestations

PLP manifests across four primary dimensions: pain intensity, frequency of episodes, duration, and description of pain qualities [36].

4.1. Pain Intensity

One study using the McGill Pain Questionnaire found that PLP intensity was comparable to chronic low back pain, non-terminal cancer pain, and labor pain [37]. Another study reported an average PLP intensity of 5.3/10 on a numerical rating scale [1].

4.2. Frequency of Episodes

PLP is typically intermittent, with only a minority of patients experiencing constant pain. Episodes often occur daily, every few days, or weekly, and less commonly monthly or yearly [3].

4.3. Duration

The duration is typically a few seconds, several minutes, or a few hours, and rarely extends to several days or longer [3].

4.4. Description of Pain Qualities

PLP is often described as “crushing,” “cutting,” or “drilling” pain [35]. PLP is not a singular symptom but a cluster of overlapping and coexisting symptoms, each of which presents with varying intensity and frequency, making it difficult for patients to articulate verbally. A multicenter cross-sectional study found that trauma-induced lower-limb amputees required a median of 13 descriptors (range: 6-20) to express their sensations, with 30% of patients needing to use more than 10 descriptors [38]. In addition to pain, the most frequent descriptors described by subjects for 7 consecutive days in a week included: burning, stinging, coldness, throbbing, and electric shocks. The complaints were listed in descending order of frequency as follows: movement sensation, itching, electric shock sensation, stinging sensation, and pulsating sensation. The intensity of each pain characteristic, as per the visual analog scale, was ranked in descending order as follows: electric shock, burning, stinging, and pricking [38].

4.5. Somatotopic Distribution

PLP primarily localizes to the distal phantom limb (e.g., fingers/palms for upper-limb amputees; toes/dorsum/ball/ankle for lower-limb amputees).

4.6. Temporal Course

Up to 90.0% of amputees develop neuropathic pain within days to weeks post-amputation, with severity escalating significantly within 1 year [39]. It is estimated that 65% of amputees experience PLP within 1 month, and 82% within 1 year [40].

5. Diagnosis and Differential Diagnosis

5.1. Assessment

The Visual Analog Scale (VAS), Numeric Rating Scale (NRS), and McGill Pain Questionnaire (MPQ) are the most commonly used tools for measuring PLP. The Chinese Scale for Neuropathic Pain Diagnosis and Efficacy Assessment is a multidimensional pain assessment tool suitable for evaluating PLP in Chinese populations [41]. The Prosthesis Evaluation Questionnaire (PEQ) assesses non-painful PLS. Pain severity should be measured through both the average and worst pain intensity experienced over at least one week [42]. Psychological assessment is an essential part of PLP evaluation [43].

5.2. Diagnosis

Currently, no physiological or molecular biomarkers can definitively predict the development of PLP post-amputation [44]. Therefore, the clinical diagnosis of PLP relies on patient history and physical examination [45]. The nonspecific and highly variable symptoms of PLP make diagnosis challenging, requiring a comprehensive medical history, examinations, testing, and exclusion of other potential neuropathies.

First, the distinction between PLS and PLP must be clarified. PLS refers to the non-painful perception of the absent limb after amputation [1]. PLP is a type of PLS characterized primarily by pain, with the following manifestations:

(1) Persistent perception of the amputated limb accompanied by severe pain;

(2) Clinical manifestations consistent with characteristic PLP features;

(3) Physical examination reveals significant tenderness at the residual limb, hardened scar tissue, tenderness along the proximal nerve trunk, sensitive skin at the residual limb, and slight touch or pressure on trigger points can cause radiating PLP;

It should be differentiated from RLP after amputation. When it is difficult to distinguish from RLP, diagnostic block can be performed. Local injection often alleviates RLP but does not relieve PLP.

Imaging characteristics: Although the cause of PLP may not be the swollen neuroma itself, locating the injured nerve and scanning distally often reveals a hypoechoic mass (swollen neuroma) [46].

5.3. Differential Diagnosis

5.3.1. Residual Limb Pain

The International Association for the Study of Pain (IASP) defines RLP as pain in the remaining portion of the amputated limb [1]. While common in the early post-amputation period, most cases resolve with wound healing. Clinical examination frequently identifies pain-generating pathologies such as infection, osteophyte formation, neuromas, or restrictive scar tissue formation. Further assessment may demonstrate hyperalgesia and allodynia [47]. Although PLP and RLP frequently coexist, RLP typically occurs immediately post-amputation and often resolves with treatment of the underlying cause, whereas PLP may dominate 1-12 months

post-amputation, is typically refractory to standard therapies, and shows no correlation with surgical wound healing progresses [4].

5.3.2. Chronic Low Back Pain

Studies indicate higher prevalence of back pain in amputees versus the general population [48]. Careful differentiation is required when pain originates from facet joints or sacroiliac joints, which patients may misinterpret as PLP in lower-limb amputees.

5.3.3. Vascular Pain

As most amputations result from vascular insufficiency, ischemic injury must be excluded in PLP patients. Distal perfusion testing (e.g., transcutaneous oxygen tension <20 mmHg at stump level indicates ischemia) can rule out vascular etiologies.

5.3.4. Neuroma-related Pain

A positive Tinel's sign is a classic feature of a neuroma. Percussion of the injured nerve or neuroma can trigger pain in the residual limb stump.

5.3.5. Prosthesis-related Pain

Shrinkage of the residual limb may cause the stump shape to no longer match the original mold, potentially leading to skin erosion at pressure points. A careful soft tissue examination of the stump can effectively rule this out.

5.3.6. Infection

Conditions such as osteomyelitis or stump infection should be excluded as potential causes of pain.

6. Treatment Methods

The primary databases searched for this consensus include PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang Data. The evidence quality rating and recommendation grading were both referenced from internationally established standards [49]. The evidence levels are classified as A, B, and C. For details, see [Tables 1 and 2](#).

Table 1. Levels of evidence.

Levels of evidence	Definition
A	Data derived from multiple randomized clinical trials or meta-analyses
B	Data derived from a single randomized clinical trial or large non-randomized studies
C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries

Table 2. *Classes of recommendations.*

	Definition	Wording to use
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended or is indicated
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of given treatment or procedure	
Class IIa	Weight of evidence/opinion is in favour of usefulness/efficacy	Should be considered
Class IIb	Usefulness/efficacy is less well established by evidence/opinion	May be considered
Class III	Evidence or general agreement that the given treatment or procedure is not usefulness/effective, and in some cases may be harmful	Is not recommended

6.1. Pharmacological Management

The selection of medications for PLP should consider multiple factors, such as analgesic efficacy, adverse effects, management of accompanying sleep and emotional disorders, drug interactions, risk of substance abuse, and cost-effectiveness of treatment [50, 51]. Drug therapy should be individualized. If monotherapy fails to provide satisfactory pain relief, combination therapy should be considered.

6.1.1. Calcium Channel Modulators

Gabapentin is commonly used for neuropathic pain management. Its primary mechanism involves binding to the $\alpha_2\delta$ subunit of voltage-gated calcium channels, thereby reducing calcium influx [52, 53]. This action decreases excitatory neurotransmitter release and suppresses both hyperalgesia and central sensitization. Clinical studies demonstrate that gabapentin monotherapy is superior to placebo in alleviating PLP [54, 55].

Evidence level: A; Recommendation grade: I.

Currently, only limited case reports exist regarding pregabalin application for PLP [56, 57]. Evidence level: C; Recommendation grade: IIb.

6.1.2. Tricyclic Antidepressants

Amitriptyline, a traditional antidepressant, exerts analgesic effects primarily through selective inhibition of serotonin and norepinephrine reuptake, thereby enhancing endogenous pain inhibition in the central nervous system. It demonstrates efficacy in various neuropathic pain conditions, including PLP. Common adverse effects are primarily anticholinergic and cardiovascular reactions, such as dry mouth, constipation, dysuria, nausea, vomiting, tachycardia, and orthostatic hypotension [58]. Two randomized controlled trials comparing amitriptyline with placebo yielded conflicting results [59].

Evidence level: B; Recommendation grade: “II”

6.1.3. Calcitonin

Calcitonin is secreted by the parafollicular C cells of the thyroid gland and reduces blood calcium levels by inhibiting osteoclast activity. Recombinant human calcitonin has been used to treat osteoporosis and osteolytic pain. A double-blind crossover trial demonstrated that intravenous administration of 200 U calcitonin is effective in treating PLP [60].

Evidence level: B; Recommendation grade: IIa.

6.1.4. NMDA Receptor Antagonists

Hyperactivity of NMDA receptors may be one of the factors contributing to the maintenance of PLP [61]. Studies have shown that ketamine administration can significantly increase pain thresholds in patients with PLP. NMDA receptor antagonists may be effective for PLP, but may cause adverse effects including cystitis, hallucinations, and cardiovascular effects [61, 62]. Dextromethorphan has shown effectiveness in alleviating PLP with a more favorable side effect profile compared to ketamine [63].

Evidence level: A; Recommendation grade: I.

Memantine is an NMDA glutamate receptor antagonist that can alleviate symptoms of neuropathic pain, including PLP [64]. Research by Hackworth et al. [65] demonstrated that memantine reduces acute and subacute PLP. However, this medication has not been proven effective for chronic PLP [66, 67].

Evidence level: A; Recommendation grade: “II”

6.1.5. Opioid Analgesics

Common opioid medications include morphine, oxycodone, and fentanyl. These medications exert their therapeutic effects by binding to opioid receptors in pain perception and modulation regions such as the spinal cord, medulla oblongata, midbrain, and thalamus, thereby elevating pain thresholds and reducing pain perception. Clinical studies have demonstrated that morphine can significantly alleviate pain symptoms in PLP patients compared to control groups [68, 69]. However,

opioid therapy may be associated with notable adverse effects including fatigue, dizziness, sweating, constipation, dysuria, nausea, vertigo, pruritus, and shortness of breath [68].

Evidence level: A; Recommendation grade: I.

6.2. Physical Therapy

Current physical therapy approaches for PLP primarily include transcutaneous electrical nerve stimulation (TENS) [70] and repetitive transcranial magnetic stimulation (rTMS) [71]. (See Figures 1, 2).



Figure 1. Patient with PLP after left lower limb amputation receiving TENS therapy. The mechanism of TENS involves activating low-threshold A β fibers to close the spinal 'gates' for pain.




Figure 2. Schematic diagram of rTMS. During rTMS, an electric current is used to create a repetitively pulsed magnetic field. When applied over the scalp, this induces an electric current within a discrete area of the brain with resultant changes in neuronal polarization. The end result is altered neuronal activity in the area where the rTMS is applied.

TENS is a non-invasive therapy based on the “gate control theory”. Its mechanism involves activation of low-threshold A β fibers to close pain gates, while simultaneously initiating the endogenous analgesic system to release endorphins and enkephalins. This upregulates or activates opioid receptors, thereby alleviating PLP [72]. Multiple studies have reported

TENS's positive effects in treating PLP [73, 74]. Lundeberg's study involving 24 PLP patients, TENS achieved a 75% pain relief rate compared to 44% with placebo [75]. Two domestic studies randomized patients into control (mirror therapy alone) and treatment (TENS + mirror therapy) groups, demonstrating superior efficacy with combined therapy [76, 77]. A recent Cochrane review noted that while multiple studies show TENS reduces visual analog scale, McGill Pain Questionnaire, and general pain scores in PLP, methodological heterogeneity precludes definitive recommendations [78].

Evidence level: A; Recommendation grade: “II”.

rTMS is a non-invasive neuromodulation technique that uses magnetic fields to induce cortical currents, thereby modulating neuronal activity. By stimulating specific brain regions to alter neural network patterns, rTMS can alleviate pain and improve neurological function [71, 79-81]. Studies have shown a significantly increase in serum β -endorphin levels post-rTMS, suggesting an analgesic effect mediated by β -endorphin [79]. A systematic review found 18 of 24 studies demonstrated rTMS's significant efficacy for neuropathic pain including PLP [82]. Currently regarded as a safe, non-invasive approach with therapeutic potential, rTMS requires further investigation.

Evidence level: A; Recommendation grade: I.

6.3. Psychological Therapy

PLP, due to its unique pain mechanisms - particularly involving central sensitization and cortical plasticity - is recognized as a chronic pain disorder with distinct biological, psychological, and social multifactorial influences [83-85]. Mechanisms such as cortical reorganization, memory alterations, and catastrophic thinking have been increasingly validated, making psychotherapeutic interventions targeting central cortical modulation one of the key treatment approaches for PLP [84, 85]. Psychological interventions addressing trauma or pain-related memories have been shown to achieve long-term, significant relief from PLP [86]. Therapies addressing unresolved trauma and pain-related memories can reduce the intensity of PLP by diminishing the emotional dimension of these memories or integrating somatic memories.

Commonly used psychotherapeutic approaches include cognitive-behavioral therapy, psychodynamic therapy, motivational interviewing, and supportive psychotherapy. Among these, mirror therapy, graded motor imagery (GMI), and virtual reality (VR) therapy are commonly applied in the treatment of PLP.

Mirror therapy utilizes visual feedback from a mirror to create the illusion of the “reappearance” of the missing limb, thereby treating PLP. Amputees who underwent 4 weeks of mirror training showed significant pain reduction [87-89]. These findings suggest that visual feedback can modulate PLP. The method is simple, requires no specialized equipment or complex setup, and demonstrates clear clinical efficacy [90].

However, further refinement is needed in methodology, treatment duration, and other aspects. The evidence level is A, with a recommendation grade I. (See [Figure 3](#)).



Figure 3. Schematic diagram of mirror therapy. Mirror therapy utilizes visual feedback from a mirror to create the illusion of the missing limb's reappearance with the aim of treating PLP.

GMI typically involves a 4-6 week treatment cycle. It generally progresses through three phases: preparation for the motor imagery program, imagined movement training, and graded mirror movement adaptation. Throughout the treatment, physiotherapists conduct weekly consultations, monitoring, and discussions based on the patient's pain improvement. GMI treatment usually leads to improvements in both pain and functional outcomes for phantom limb pain patients, with these benefits maintained during 6-month follow-ups [91, 92]. The evidence level is B, with a recommendation grade of IIa.

VR refers to computer technology that simulates human sensory experiences to create an immersive three-dimensional environment, making users feel physically present within it [93]. This technology exerts broad regulatory effects on cognitive functions, including: enhancing attention and reaction speed, improving spatial perception and memory, and facilitating emotional experience and cognitive processing. In therapeutic applications, VR can generate a virtual, intact avatar, where movements of the amputee's residual limb are translated into motions of the virtual limb. This approach enables relaxation and exercise training, thereby alleviating pain [94, 95]. Such immersive therapy shows promising potential for more effective PLP management in the future. The evidence level is C, with a recommendation grade of IIb.

Mental imagery, phantom exercise training, and sensory discrimination training can also improve pain intensity and

functional outcomes in PLP [96, 97].

6.4. Traditional Chinese Medicine (TCM) Treatment

Several studies have explored acupuncture as an adjunctive therapy for PLP. Trevelyan et al. [98] conducted a multicenter randomized controlled trial and concluded that acupuncture may be effective in treating PLP. Freed et al. [99] investigated the therapeutic effects of acupuncture on post-traumatic mental disorders and PLP, demonstrating that acupuncture influences cortical brain function. Other reports primarily consist of case studies, such as auricular acupuncture for PLP [100], scalp acupuncture [101], and electroacupuncture [102], all of which yielded satisfactory outcomes. Additionally, acupuncture applied to the contralateral (healthy) limb has been used to treat PLP with positive results [103].

For TCM acupuncture in PLP management, the evidence level is B, with a recommendation grade of IIa."

6.5. Herbal Medicine Treatment'

The Jianghuang Gegen (The herbal formula includes *Curcumae Longae Rhizoma* and *Puerariae Lobatae Radix*) Decoction, administered orally for 6 weeks in combination with comprehensive therapies (e.g., exercise therapy, mirror therapy, electrical stimulation), has been shown to improve the treatment efficacy rate from 80% to 95% in managing PLP after diabetic foot amputation, though it does not enhance the cure rate [104]. External herbal washes containing *Schizonepeta tenuifolia* (Jingjie) and *Saposhnikovia divaricata* (Fangfeng), when used in combination with multimodal therapy, have been shown to significantly reduce pain assessment scores in patients with post-traumatic PLP. Additionally, oral herbal medicine and topical herbal washes for traumatic upper- or lower-limb amputations have demonstrated improved overall efficacy rates and reduced visual analog scale (VAS) scores, with no significant differences between upper- and lower-limb subgroups [105]. Haitongpi (a herbal name) Decoction steam therapy as a primary treatment for unilateral traumatic PLP has been found to significantly decrease pain assessment indices, present pain intensity scores, VAS scores, and depression scores [106].

Evidence level: B; Recommendation grade: IIb.

6.6. Nerve Block Therapy

Nerve block therapy serves as a critical intervention for PLP.

For lower extremity pain management, common nerve block techniques include sciatic nerve block, femoral nerve block, lumbar plexus block, tibial nerve block, common peroneal nerve block, and lumbar sympathetic ganglion block. For upper extremity pain, standard approaches include involve brachial plexus block, median nerve block, radial nerve

block, and ulnar nerve block.

The selection of nerve block technique depends on the amputation level of the affected limb:

Lumbar sympathetic ganglion block is indicated for above-knee amputations or below-knee amputations secondary to peripheral vascular disease or trauma [107];

Brachial plexus block is indicated for Selective above-elbow amputations (tumor-related) [108], Below-elbow amputations (infraclavicular approach), Shoulder disarticulations (interscalene approach) [109, 110].

Radial, ulnar, and median nerve blocks are indicated for Single-digit amputations (selection of individual or combined blocks based on digital nerve distribution) [111] or Wrist-level amputations [112].

Sciatic and femoral nerve blocks are indicated for unilateral below-knee amputations or Unilateral above-knee amputations due to peripheral vascular disease [113-118].

Lumbar plexus block is indicated for Unilateral below-hip amputations caused by malignancy or trauma [113, 119].

Tibial and common peroneal nerve blocks are indicated for Below-knee amputations, Ankle-level or digital foot amputations (single/combined blocks based on neural distribution) [120].

Commonly used local anesthetics and their concentrations include 0.5% ropivacaine/0.75% ropivacaine/0.25% bupivacaine/2% lidocaine [107-119]. The nerve block technique may be administered as either single-shot injection or continuous catheter infusion.

Overall, nerve block therapy demonstrates significant efficacy in alleviating PLP and improving patients' quality of life, though the degree and duration of pain relief vary individually. While peripheral nerve blocks typically provide acute pain relief, some patients can achieve long-term therapeutic benefits [113, 120]. Borghi et al. [114] demonstrated that sciatic nerve blocks may reduce the incidence of PLP in amputees. Studies indicate that 6-day peripheral nerve blockade can provide pain relief persisting at both 4 weeks and 6-month follow-up [112, 113, 121]. According to the Practice Guidelines for Chronic Pain Management by the American Society of Anesthesiologists (ASA), lumbar sympathetic nerve blockade is indicated as a therapeutic option for PLP. Case report studies have demonstrated that lumbar sympathetic block is both safe and effective for alleviating PLP symptoms [107]. However, its therapeutic effectiveness remains debated. A randomized, double-blind study evaluating the impact of sciatic nerve block on chronic pain development at 6 months post traumatic below-knee amputation demonstrated that preemptive sciatic nerve blockade failed to reduce either the incidence or severity of chronic post-amputation pain [115]. Although nerve blocks can provide effective pain relief, there are some potential risks and adverse effects, including hematoma, sensory loss, local infection, etc. The approach to nerve blocks should be individualized, requiring close collaboration between the physician and the patient to develop the most appropriate treatment

plan based on the characteristics of the pain and the patient's overall health condition. In summary, nerve block therapy plays a significant role in the management of phantom limb pain. Despite some potential risks and controversial conclusions, nerve blocks remain an important component of phantom limb pain treatment. Patients and physicians should work closely together and continuously monitor symptoms during the treatment process to ensure the effectiveness and safety of the treatment.

The evidence level is A, and the recommendation level is I.

6.7. Radiofrequency Therapy

Radiofrequency therapy is a commonly used nerve-targeting treatment for PLP encompassing two main types: radiofrequency ablation and pulsed radiofrequency. The principle of this technique involves placing an electrode directly or via targeted puncture near a peripheral nerve or the dorsal root ganglion (DRG), then applying electrical current to modulate or disrupt the transmission of pain signals to the central nervous system, ultimately achieving pain relief or elimination.

6.7.1. Radiofrequency Ablation

Current evidence suggests that radiofrequency ablation has a certain therapeutic effect on pain caused by stump neuromas after amputation [122, 123]. Additionally, for PLP, targeting peripheral nerves with radiofrequency ablation can also play a positive therapeutic role [124]. Although radiofrequency ablation has shown some efficacy in the treatment of PLP, there are also some limitations and risks. Radiofrequency ablation is a destructive and invasive treatment method, and there is currently no evidence-based medical evidence to clearly support its application in PLP.

6.7.2. Pulsed Radiofrequency

Pulsed radiofrequency (PRF) delivers intermittent high-frequency electrical currents to neural tissue while avoiding thermal damage. Small-scale studies have demonstrated that PRF targeting the L4 and L5 dorsal root ganglia (DRG), as well as peripheral PRF modulation of the femoral and sciatic nerves, can effectively alleviate refractory PLP [125, 126]. DRG radiofrequency modulation may represent a promising therapeutic approach for PLP, with benefits including pain reduction, alleviation of anxiety and depression, and improved quality of life [127]. However, further research is needed to establish clinical recommendations. Current evidence level: C; Recommendation grade: IIa.

6.8. Neuromodulation

Neuromodulation includes methods such as spinal cord stimulation (SCS) and deep brain stimulation (DBS). These treatment approaches aim to alleviate PLP by altering neuronal excitability and modulating neural signal transmission.

6.8.1. Spinal Cord Stimulation

SCS is based on the gate control theory, which alleviates pain by continuously stimulating the A β nerve fibers in the dorsal column of the spinal cord, thereby interfering with or blocking the transmission of pain signals through C and A δ nerve fibers to the central nervous system [128]. SCS has been used for the treatment of PLP for over 50 years [129]. Recent studies have shown that SCS can alter the excitability of “wide-dynamic-range” neurons, promote physiological inhibitory mechanisms, and modify the activity of various neurotransmitters [130]. Multiple studies have demonstrated positive therapeutic effects of SCS in treating PLP [131]. A systematic review revealed that 7 out of 12 included studies indicated significant improvement in PLP with SCS, while the remaining 5 showed no efficacy [132]. Based on current evidence, spinal cord stimulation is considered a viable alternative to traditional treatments for PLP.

Evidence level C, recommendation grade IIa.

6.8.2. Deep Brain Stimulation

DBS involves implanting tiny electrodes into specific brain regions and connecting them to a pulse generator, which can be programmed via an external device to apply electrical stimulation to alter neural activity, thereby alleviating or improving neurological disorders. Studies have reported that the overall pain relief rate of DBS in the treatment of PLP is approximately 50% to 91% [133]. However, the application of DBS in the treatment of PLP is still in the research stage and is not a conventional treatment strategy. With advancements in science and technology and a deeper understanding of the mechanisms of PLP, DBS may become an effective treatment in the future. Nevertheless, strict evaluation and selection of patients are still required before using DBS to treat PLP to ensure the safety and effectiveness of the treatment.

Evidence Level C, Recommendation Level IIb.

6.9. Surgical Intervention

For patients who have not responded well to conservative and minimally invasive interventional treatments, surgical intervention may be considered. Given the complex peripheral and central mechanisms, as well as the biopsychosocial factors involved in PLP, the efficacy of various surgical procedures remains unclear. It is recommended to maximize patient benefits by considering the patient's condition and etiology, comprehensively evaluating the risk-benefit ratio, and formulating a personalized surgical plan.

Traditional surgical approaches for peripheral involvement mechanisms such as neuroma commonly employ neurotomy and nerve implantation to treat PLP. Current research indicates that modified techniques such as targeted nerve implantation and combined collagen nerve wrapping offer better treatment options [134]. Compared to traditional surgery, targeted muscle reinnervation surgery and peripheral nerve interface regeneration can further alleviate PLP through bi-

onic reconstruction and improved prosthetic function. Multiple studies currently support their positive role in the treatment and rehabilitation of PLP [135, 136], with functional prosthetics proving more effective than cosmetic prosthetics, as their myoelectric function addresses the issue of sensorimotor feedback post-amputation [137, 138].

Evidence level B, recommendation grade IIa.

Dorsal root entry zone lesioning is a classic surgical procedure for treating brachial plexus root avulsion. A retrospective analysis showed that among 37 patients who underwent this surgery, 45.9% experienced disappearance or alteration of PLS, and 67.6% experienced relief from PLP. The differences may be influenced by changes at the supraspinal level and central plasticity [139].

Evidence level C, recommendation grade IIa.

Cryoneurolysis blocks pain signal transmission by freezing nerves at low temperatures (commonly using nitrous oxide at about -70°C). Multiple cohort studies have shown it to be safe and effective in treating PLP. However, a multicenter randomized controlled trial by Ilfeld et al. [140] indicated that ultrasound-guided percutaneous cryoneurolysis provided no significant benefit for PLP after 4 months. Patients with transtibial amputations showed better outcomes compared to those with transankle-foot and transfemoral amputations [141]. Evidence level A, recommendation grade “II”

6.10. Other Treatment Modalities

A Delphi expert consensus study suggested that addressing neural mechanisms in the brain, such as cortical functional reorganization, may alleviate phantom limb pain [85]. Sensory discrimination training is a technique that provides sensory input to the residual limb's adjacent areas using fabrics with varying softness/texture (e.g., cotton vs. hook-and-loop fasteners). By resolving the mismatch between the brain's sensory output and amputated limb's feedback, this approach promotes cortical reorganization and pain reduction [142-144].

7. Prevention and Prognosis

Some clinical trials have shown that epidural preemptive analgesia and postoperative regional blocks are effective in preventing PLP, but there are limitations in study design and small sample sizes. Therefore, larger-scale, well-designed, randomized controlled clinical trials are needed to better determine whether regional block can prevent and reduce the occurrence of PLP [43]. In addition to regional block, it has been shown that the NMDA receptor antagonist memantine significantly reduces the incidence of phantom limb pain compared to placebo [2]. There is no evidence that reducing the severity of phantom limb pain improves function. phantom limb pain is associated with depressive symptoms, which may reduce treatment efficacy, function, and quality of life. Severe phantom limb pain has a negative impact on

daily activities, prosthetic use, mobility, and social activities [145].

The diagnosis and treatment of PLP are highly challenging. The Chinese Journal of Painology has organized domestic experts to propose diagnostic and therapeutic recommendations and formulate this consensus based on summarizing the current evidence both domestically and internationally, aiming to provide a basis for clinical diagnosis and treatment. However, research on phantom limb pain remains insufficient to date. There is an urgent need to conduct large-sample, multicenter randomized controlled studies combined with real-world studies to obtain more robust evidence-based evidence to assist in precise diagnosis and individualized treatment, thereby helping more patients alleviate pain. Furthermore, due to the complexity of clinical practical issues, it is hoped that experts and physicians in related fields will actively provide feedback and suggestions. It is also anticipated that new clinical practice issues can be further collected in the future to supplement and revise the consensus.

Abbreviations

PLP	Phantom Limb Pain
PLS	Phantom Limb Sensation
RLP	Residual Limb Pain

Conflicts of Interest

The authors declare no conflicts of interest.

References

- [1] Urits I, Seifert D, Seats A, et al. Treatment strategies and effective management of phantom limb-associated pain [J]. *Curr Pain Headache Rep*, 2019, 23(9): 64. <https://doi.org/10.1007/s11916-019-0802-0>
- [2] Flor H. Phantom-limb pain: characteristics, causes, and treatment [J]. *Lancet Neurol*, 2002, 1(3): 182-189. [https://doi.org/10.1016/s1474-4422\(02\)00074-1](https://doi.org/10.1016/s1474-4422(02)00074-1)
- [3] Nikolajsen L, Staehelin Jensen T. Phantom limb pain [J]. *Curr Rev Pain*, 2000, 4(2): 166-170. <https://doi.org/10.1007/s11916-000-0052-0>
- [4] Culp CJ, Abdi S. Current understanding of phantom pain and its treatment [J]. *Pain Physician*, 2022, 25(7): E941-E957.
- [5] Browne JD, Fraiser R, Cai Y, et al. Unveiling the phantom: what neuroimaging has taught us about phantom limb pain [J]. *Brain Behav*, 2022, 12(3): e2509. <https://doi.org/10.1002/brb3.2509>
- [6] Aternali A, Katz J. Recent advances in understanding and managing phantom limb pain [J]. *F1000Res*, 2019, 8. <https://doi.org/10.12688/f1000research.19355.1>
- [7] Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey [J]. *Pain*, 1984, 18(1): 83-95. [https://doi.org/10.1016/0304-3959\(84\)90128-3](https://doi.org/10.1016/0304-3959(84)90128-3)
- [8] GBD 2017 disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. *Lancet*, 2018, 392(10159): 1789-1858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7) Erratum in: *Lancet*. 2019, 393(10190): e44.
- [9] Zhu TQ, Jiang ZB, Zhao JM, et al. Epidemiological investigation of phantom limb pain in Guangxi [J]. *Journal of Guangxi Medical University*, 2009, 26(6): 980-982. <https://doi.org/10.3969/j.issn.1005-930X.2009.06.066>
- [10] Dijkstra PU, Geertzen JH, Stewart R, et al. Phantom pain and risk factors: a multivariate analysis [J]. *J Pain Symptom Manage*, 2002, 24(6): 578-585. [https://doi.org/10.1016/s0885-3924\(02\)00538-9](https://doi.org/10.1016/s0885-3924(02)00538-9)
- [11] Jensen TS, Krebs B, Nielsen J, et al. Phantom limb, phantom pain and stump pain in amputees during the first 6 months following limb amputation [J]. *Pain*, 1983, 17(3): 243-256. [https://doi.org/10.1016/0304-3959\(83\)90097-0](https://doi.org/10.1016/0304-3959(83)90097-0)
- [12] Nikolajsen L, Ilkjaer S, Krøner K, et al. The influence of preamputation pain on postamputation stump and phantom pain. *Pain*. 1997; 72(3): 393-405. [https://doi.org/10.1016/s0304-3959\(97\)00061-4](https://doi.org/10.1016/s0304-3959(97)00061-4)
- [13] Limakatso K, Bedwell GJ, Madden VJ, et al. The prevalence and risk factors for phantom limb pain in people with amputations: a systematic review and meta-analysis [J]. *PLoS One*, 2020, 15(10): e0240431. <https://doi.org/10.1371/journal.pone.0240431>
- [14] Bosmans JC, Geertzen JH, Post WJ, et al. Factors associated with phantom limb pain: a 31/2-year prospective study [J]. *Clin Rehabil*, 2010, 24(5): 444-453. <https://doi.org/10.1177/0269215509360645>
- [15] Karanikolas M, Aretha D, Tsolakis I, et al. Optimized perioperative analgesia reduces chronic phantom limb pain intensity, prevalence, and frequency: a prospective, randomized, clinical trial [J]. *Anesthesiology*, 2011, 114(5): 1144-1154. <https://doi.org/10.1097/ALN.0b013e31820fc7d2>
- [16] Vaso A, Adahan HM, Gjika A, et al. Peripheral nervous system origin of phantom limb pain [J]. *Pain*, 2014, 155(7): 1384-1391. <https://doi.org/10.1016/j.pain.2014.04.018>
- [17] Zhang XL, Albers KM, Gold MS. Inflammation-induced increase in nicotinic acetylcholine receptor current in cutaneous nociceptive DRG neurons from the adult rat [J]. *Neuroscience*, 2015, 284: 483-499. <https://doi.org/10.1016/j.neuroscience.2014.10.018>
- [18] Navarro X, Vivó M, Valero-Cabré A. Neural plasticity after peripheral nerve injury and regeneration [J]. *Prog Neurobiol*, 2007, 82(4): 163-201. <https://doi.org/10.1016/j.pneurobio.2007.06.005>

- [19] Cirillo G, Colangelo AM, Berbenni M, et al. Purinergic modulation of spinal neuroglial maladaptive plasticity following peripheral nerve injury [J]. *Mol Neurobiol*, 2015, 52(3): 1440-1457. <https://doi.org/10.1007/s12035-014-8943-y>
- [20] Katz J, Melzack R. Pain 'memories' in phantom limbs: review and clinical observations [J]. *Pain*, 1990, 43(3): 319-336. [https://doi.org/10.1016/0304-3959\(90\)90029-D](https://doi.org/10.1016/0304-3959(90)90029-D)
- [21] Feng AM, Lian YY, Liu H, et al. Effects of substitute stimulation on post-amputation behavior in rats [J]. *Chinese Journal of Pain Medicine*, 2012, 18(9): 548-551. <https://doi.org/10.3969/j.issn.1006-9852.2012.09.013>
- [22] Xue MM, Lei J, You HJ. Mechanisms and clinical treatment of phantom limb pain [J]. *Chinese Journal of Pain Medicine*, 2021, 27(12): 883-887. <https://doi.org/10.3969/j.issn.1006-9852.2021.12.002>
- [23] Collins KL, Russell HG, Schumacher PJ, et al. A review of current theories and treatments for phantom limb pain [J]. *J Clin Invest*, 2018, 128(6): 2168-2176. <https://doi.org/10.1172/JCI94003>
- [24] Flor H, Elbert T, Knecht S, et al. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation [J]. *Nature*, 1995, 375(6531): 482-484. <https://doi.org/10.1038/375482a0>
- [25] Lotze M, Flor H, Grodd W, et al. Phantom movements and pain. An fMRI study in upper limb amputees [J]. *Brain*. 2001. 124(Pt 11): 2268-2277. <https://doi.org/10.1093/brain/124.11.2268>
- [26] Duarte D, Bauer C, Pinto CB, et al. Cortical plasticity in phantom limb pain: a fMRI study on the neural correlates of behavioral clinical manifestations [J]. *Psychiatry Res Neuroimaging*, 2020, 304: 111151. <https://doi.org/10.1016/j.psychresns.2020.111151>
- [27] Zheng BX, Yin Y, Xiao H, et al. Altered cortical reorganization and brain functional connectivity in phantom limb pain: a functional MRI study [J]. *Pain Pract*, 2021, 21(4): 394-403. <https://doi.org/10.1111/papr.12966>
- [28] Melzack R. Pain and the neuromatrix in the brain [J]. *J Dent Educ*, 2001, 65(12): 1378-1382.
- [29] Jin QQ, Tang DD, Peng WW, et al. Research advances in pathological mechanisms of phantom limb pain [J]. *Progress in Physiological Sciences*, 2015; (5): 341-346.
- [30] Anderson-Barnes VC, McAuliffe C, Swanberg KM, et al. Phantom limb pain-a phenomenon of proprioceptive memory?[J]. *Med Hypotheses*, 2009, 73(4): 555-558. <https://doi.org/10.1016/j.mehy.2009.05.038>
- [31] Du X, Hao H, Yang Y, et al. Local GABAergic signaling within sensory ganglia controls peripheral nociceptive transmission [J]. *J Clin Invest*, 2017, 127(5): 1741-1756. <https://doi.org/10.1172/JCI86812>
- [32] Pattany PM, Yezierski RP, Widerström-Noga EG, et al. Proton magnetic resonance spectroscopy of the thalamus in patients with chronic neuropathic pain after spinal cord injury [J]. *AJNR Am J Neuroradiol*, 2002, 23(6): 901-905.
- [33] Waxman SG, Hains BC. Fire and phantoms after spinal cord injury: Na⁺ channels and central pain [J]. *Trends Neurosci*, 2006, 29(4): 207-215. <https://doi.org/10.1016/j.tins.2006.02.003>
- [34] Pu S, Wu Y, Tong F, et al. Mechanosensitive ion channel TMEM63A gangs up with local macrophages to modulate chronic post-amputation pain [J]. *Neurosci Bull*, 2023, 39(2): 177-193. <https://doi.org/10.1007/s12264-022-00910-0>
- [35] Niraj S, Niraj G. Phantom limb pain and its psychologic management: a critical review [J]. *Pain Manag Nurs*, 2014, 15(1): 349-364. <https://doi.org/10.1016/j.pmn.2012.04.001>
- [36] Weeks SR, Anderson-Barnes VC, Tsao JW. Phantom limb pain: theories and therapies [J]. *Neurologist*, 2010, 16(5): 277-286. <https://doi.org/10.1097/NRL.0b013e3181edf128>
- [37] Hill A. Phantom limb pain: a review of the literature on attributes and potential mechanisms [J]. *J Pain Symptom Manage*, 1999, 17(2): 125-142. [https://doi.org/10.1016/s0885-3924\(98\)00136-5](https://doi.org/10.1016/s0885-3924(98)00136-5)
- [38] Sugawara AT, Simis M, Fregni F, et al. Characterisation of Phantom Limb Pain in Traumatic Lower-Limb Amputees. *Pain Res Manag*. 2021; 2021: 2706731. <https://doi.org/10.1155/2021/2706731>
- [39] Kuffler DP. Evolving techniques for reducing phantom limb pain [J]. *Exp Biol Med (Maywood)*, 2023, 248(7): 561-572. <https://doi.org/10.1177/15353702231168150>
- [40] Stankevicius A, Wallwork SB, Summers SJ, et al. Prevalence and incidence of phantom limb pain, phantom limb sensations and telescoping in amputees: A systematic rapid review [J]. *Eur J Pain*, 2021, 25(1): 23-38. <https://doi.org/10.1002/ejp.1657>
- [41] Jiang ZB, Zhao P, Lyu J, et al. Development and validation of the Chinese Scale for Neuropathic Pain Diagnosis and Efficacy Assessment [J]. *Chinese Journal of Painology*, 2022; 18(4): 466-475. <https://doi.org/10.3760/cma.j.cn101658-20220705-00106>
- [42] Ferraro F, Jacopetti M, Spallone V, et al. Diagnosis and treatment of pain in plexopathy, radiculopathy, peripheral neuropathy and phantom limb pain. evidence and recommendations from the Italian consensus conference on pain on neurorehabilitation [J]. *Eur J Phys Rehabil Med*, 2016, 52(6): 855-866.
- [43] Luo Y, Anderson TA. Phantom limb pain: a review [J]. *Int Anesthesiol Clin*, 2016, 54(2): 121-139. <https://doi.org/10.1097/AIA.0000000000000095>
- [44] Bhomia M, Balakathiresan N, Zhai M, et al. Association of peripheral serum microRNAs with persistent phantom limb pain in individuals with amputation [J]. *Am J Phys Med Rehabil*, 2022, 101(12): 1139-1147. <https://doi.org/10.1097/PHM.0000000000001999>
- [45] Hsu E, Cohen SP. Postamputation pain: epidemiology, mechanisms, and treatment [J]. *J Pain Res*, 2013, 6: 121-136. <https://doi.org/10.2147/JPR.S32299>

- [46] Buch NS, Qerama E, Brix Finnerup N, et al. Neuromas and postamputation pain [J]. *Pain*, 2020, 161(1): 147-155. <https://doi.org/10.1097/j.pain.0000000000001705>
- [47] Nikolajsen L, Jensen TS. phantom limb pain [J]. *Br J Anaesth*. 2001; 87(1): 107-116. <https://doi.org/10.1093/bja/87.1.107>
- [48] Smith DG, Ehde DM, Legro MW, et al. Phantom limb, residual limb, and back pain after lower extremity amputations [J]. *Clin Orthop Relat Res*, 1999, (361): 29-38. <https://doi.org/10.1097/00003086-199904000-00005>
- [49] Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021; 42(14): 1289-1367. <https://doi.org/10.1093/eurheartj/ehaa575>
- [50] Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update [J]. *Mayo Clin Proc*, 2010, 85(3 Suppl): S3-14. <https://doi.org/10.4065/mcp.2009.0649>
- [51] Expert Group on Neuropathic Pain Diagnosis and Treatment. Expert consensus on diagnosis and treatment of neuropathic pain [J]. *Chinese Journal of Pain Medicine*, 2013; 19(12): 705-710. <https://doi.org/10.3969/j.issn.1006-9852.2013.12.001>
- [52] Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn [J]. *Pain*, 2000, 85(3): 405-414. [https://doi.org/10.1016/S0304-3959\(99\)00283-3](https://doi.org/10.1016/S0304-3959(99)00283-3)
- [53] Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains [J]. *Curr Opin Neurol*, 2009, 22(5): 467-474. <https://doi.org/10.1097/WCO.0b013e3283311e13>
- [54] Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study [J]. *Reg Anesth Pain Med*, 2002, 27(5): 481-486. <https://doi.org/10.1053/rapm.2002.35169>
- [55] Smith DG, Ehde DM, Hanley MA, et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain [J]. *J Rehabil Res Dev*, 2005, 42(5): 645-654. <https://doi.org/10.1682/jrrd.2005.05.0082>
- [56] Wössner S, Weber K, Steinbeck AC, et al. Pregabalin as adjunct in a multimodal pain therapy after traumatic foot amputation - A case report of a 4-year-old girl [J]. *Scand J Pain*, 2017, 17: 146-149. <https://doi.org/10.1016/j.sjpain.2017.09.001>
- [57] Spiegel DR, Lappinen E, Gottlieb M. A presumed case of phantom limb pain treated successfully with duloxetine and pregabalin [J]. *Gen Hosp Psychiatry*, 2010, 32(2): 228. e5-7. <https://doi.org/10.1016/j.genhosppsych.2009.05.012>
- [58] Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia [J]. *Drugs Aging*, 2012, 29(11): 863-869. <https://doi.org/10.1007/s40266-012-0014-3>
- [59] McCormick Z, Chang-Chien G, Marshall B, et al. Phantom limb pain: a systematic neuroanatomical-based review of pharmacologic treatment [J]. *Pain Med*, 2014, 15(2): 292-305. <https://doi.org/10.1111/pme.12283>
- [60] Simanski C, Lempa M, Koch G, et al. Phantomschmerztherapie mit lachscalcitonin und einfluss auf die postoperative Patientenzufriedenheit [Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction][J]. *Chirurg*, 1999, 70(6): 674-681. <https://doi.org/10.1007/s001040050704>
- [61] Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input [J]. *Pain*, 1996, 67(1): 69-77. [https://doi.org/10.1016/0304-3959\(96\)03080-1](https://doi.org/10.1016/0304-3959(96)03080-1)
- [62] Eichenberger U, Neff F, Svetlicic G, et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds [J]. *Anesth Analg*, 2008, 106(4): 1265-1273, table of contents. <https://doi.org/10.1213/ane.0b013e3181685014>
- [63] Ben Abraham R, Marouani N, Kollender Y, et al. Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients [J]. *Clin J Pain*, 2002, 18(5): 282-285. <https://doi.org/10.1097/00002508-200209000-00002>
- [64] Schley M, Topfner S, Wiech K, et al. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees [J]. *Eur J Pain*, 2007, 11(3): 299-308. <https://doi.org/10.1016/j.ejpain.2006.03.003>
- [65] Hackworth RJ, Tokarz KA, Fowler IM, et al. Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain [J]. *Anesth Analg*, 2008, 107(4): 1377-1379. <https://doi.org/10.1213/ane.0b013e31817f90f1>
- [66] Wiech K, Kiefer RT, Töpfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain [J]. *Anesth Analg*, 2004, 98(2): 408-413. <https://doi.org/10.1213/01.ANE.0000096002.53818.BD>
- [67] Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial [J]. *Pain*, 2003, 103(3): 277-283. [https://doi.org/10.1016/S0304-3959\(02\)00456-6](https://doi.org/10.1016/S0304-3959(02)00456-6)
- [68] Huse E, Larbig W, Flor H, et al. The effect of opioids on phantom limb pain and cortical reorganization [J]. *Pain*, 2001, 90(1-2): 47-55. [https://doi.org/10.1016/s0304-3959\(00\)00385-7](https://doi.org/10.1016/s0304-3959(00)00385-7)
- [69] Wu CL, Tella P, Staats PS, et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial [J]. *Anesthesiology*, 2002, 96(4): 841-848. <https://doi.org/10.1097/00005542-200204000-00010>

- [70] Limakatso K. Managing acute phantom limb pain with transcutaneous electrical nerve stimulation: a case report. *J Med Case Rep*. 2023; 17(1): 209. <https://doi.org/10.1186/s13256-023-03915-z>
- [71] Brandt SJ, Oral HY, Arellano-Bravo C, et al. Repetitive Transcranial Magnetic Stimulation as a Therapeutic and Probe in Schizophrenia: Examining the Role of Neuroimaging and Future Directions. *Neurotherapeutics*. 2021; 18(2): 827-844. <https://doi.org/10.1007/s13311-021-01046-1>
- [72] Gibson W, Wand BM, Meads C, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain-an overview of cochrane reviews [J]. *Cochrane Database Syst Rev*, 2019, 4(4): CD011890. <https://doi.org/10.1002/14651858.CD011890.pub3>
- [73] Giuffrida O, Simpson L, Halligan PW. Contralateral stimulation, using TENS, of phantom limb pain: two confirmatory cases [J]. *Pain Med*, 2010, 11(1): 133-141. <https://doi.org/10.1111/j.1526-4637.2009.00705.x>
- [74] Mulvey MR, Bagnall AM, Johnson MI, et al. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults [J]. *Cochrane Database Syst Rev*, 2010, (5): CD007264. <https://doi.org/10.1002/14651858.CD007264.pub2>
- [75] Lundeborg T. Relief of pain from a phantom limb by peripheral stimulation [J]. *J Neurol*, 1985, 232(2): 79-82. <https://doi.org/10.1007/BF00313905>
- [76] Zhang GX, Qiu KY. Effects of mirror therapy combined with transcutaneous electrical nerve stimulation on post-amputation phantom limb pain [J]. *Chinese Journal of Pain Medicine*, 2017; 23(4): 310-311. <https://doi.org/10.3969/j.issn.1006-9852.2017.04.016>
- [77] Zhao MZ. Effects of mirror therapy combined with transcutaneous electrical nerve stimulation on post-amputation phantom limb pain [J]. *Systems Medicine*, 2018; 3(21): 44-45. <https://doi.org/10.19368/j.cnki.2096-1782.2018.21.044>
- [78] Pacheco-Barrios K, Meng X, Fregni F. Neuromodulation techniques in phantom limb pain: a systematic review and meta-analysis [J]. *Pain Med*, 2020, 21(10): 2310-2322. <https://doi.org/10.1093/pm/pnaa039>
- [79] Malavera A, Silva FA, Fregni F, et al. Repetitive transcranial magnetic stimulation for phantom limb pain in land mine victims: a double-blinded, randomized, sham-controlled trial [J]. *J Pain*, 2016, 17(8): 911-918. <https://doi.org/10.1016/j.jpain.2016.05.003>
- [80] Ahmed MA, Mohamed SA, Sayed D. Long-term antalgic effects of repetitive transcranial magnetic stimulation of motor cortex and serum beta-endorphin in patients with phantom pain [J]. *Neurol Res*, 2011, 33(9): 953-958. <https://doi.org/10.1179/1743132811Y.0000000045>
- [81] Lefaucheur JP. Transcranial magnetic stimulation [J]. *Handb Clinical Neurophysiology*, 2019. 160: 559-580. <https://doi.org/10.1016/B978-0-444-64032-1.00037-0>
- [82] Viswanathan A, Phan PC, Burton AW. Use of spinal cord stimulation in the treatment of phantom limb pain: case series and review of the literature [J]. *Pain Pract*, 2010, 10(5): 479-484. <https://doi.org/10.1111/j.1533-2500.2010.00374.x>
- [83] Erlenwein J, Diers M, Ernst J, et al. Clinical updates on phantom limb pain [J]. *Pain Rep*, 2021, 6(1): e888. <https://doi.org/10.1097/PR9.0000000000000888>
- [84] Andoh J, Milde C, Diers M, et al. Assessment of cortical reorganization and preserved function in phantom limb pain: a methodological perspective [J]. *Sci Rep*, 2020, 10(1): 11504. <https://doi.org/10.1038/s41598-020-68206-9>
- [85] Limakatso K, Parker R. Treatment recommendations for phantom limb pain in people with amputations: an expert consensus delphi study [J]. *PM R*, 2021, 13(11): 1216-1226. <https://doi.org/10.1002/pmrj.12556>
- [86] de Roos C, Veenstra AC, de Jongh A, et al. Treatment of chronic phantom limb pain using a trauma-focused psychological approach [J]. *Pain Res Manag*, 2010, 15(2): 65-71. <https://doi.org/10.1155/2010/981634>
- [87] Chan BL, Witt R, Charrow AP, et al. Mirror therapy for phantom limb pain [J]. *N Engl J Med*, 2007, 357(21): 2206-2207. <https://doi.org/10.1056/NEJMc071927>
- [88] Rothgangel A, Braun S, Winkens B, et al. Traditional and augmented reality mirror therapy for patients with chronic phantom limb pain (PACT study): results of a three-group, multicentre single-blind randomized controlled trial [J]. *Clin Rehabil*, 2018, 32(12): 1591-1608. <https://doi.org/10.1177/0269215518785948>
- [89] Ol HS, Van Heng Y, Danielsson L, et al. Mirror therapy for phantom limb and stump pain: a randomized controlled clinical trial in landmine amputees in Cambodia [J]. *Scand J Pain*, 2018, 18(4): 603-610. <https://doi.org/10.1515/sjpain-2018-0042>
- [90] Wittkopf PG, Johnson MI. Mirror therapy: A potential intervention for pain management. *Rev Assoc Med Bras* (1992). 2017; 63(11): 1000-1005. <https://doi.org/10.1590/1806-9282.63.11.1000>
- [91] Moseley GL. Graded motor imagery for pathologic pain: a randomized controlled trial [J]. *Neurology*, 2006, 67(12): 2129-2134. <https://doi.org/10.1212/01.wnl.0000249112.56935.32>
- [92] Limakatso K, Madden VJ, Manie S, et al. The effectiveness of graded motor imagery for reducing phantom limb pain in amputees: a randomised controlled trial [J]. *Physiotherapy*, 2020, 109: 65-74. <https://doi.org/10.1016/j.physio.2019.06.009>
- [93] Teo WP, Muthalib M, Yamin S, et al. Does a combination of virtual reality, neuromodulation and neuroimaging provide a comprehensive platform for neurorehabilitation?-a narrative review of the literature [J]. *Front Hum Neurosci*, 2016, 10: 284. <https://doi.org/10.3389/fnhum.2016.00284>
- [94] Vasantachart AY, Yeo E, Chau B. Virtual and augmented reality-based treatments for phantom limb pain: a systematic review [J]. *Innov Clin Neurosci*, 2022, 19(10-12): 48-57.

- [95] Ortiz-Catalan M, Guðmundsdóttir RA, Kristoffersen MB, et al. Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain [J]. *Lancet*, 2016, 388(10062): 2885-2894. [https://doi.org/10.1016/S0140-6736\(16\)31598-7](https://doi.org/10.1016/S0140-6736(16)31598-7)
- [96] Brunelli S, Morone G, Iosa M, et al. Efficacy of progressive muscle relaxation, mental imagery, and phantom exercise training on phantom limb: a randomized controlled trial [J]. *Arch Phys Med Rehabil*, 2015, 96(2): 181-187. <https://doi.org/10.1016/j.apmr.2014.09.035>
- [97] MacIver K, Lloyd DM, Kelly S, et al. Phantom limb pain, cortical reorganization and the therapeutic effect of mental imagery [J]. *Brain*, 2008, 131(Pt 8): 2181-2191. <https://doi.org/10.1093/brain/awn124>
- [98] Trevelyan EG, Turner WA, Summerfield-Mann L, et al. Acupuncture for the treatment of phantom limb syndrome in lower limb amputees: a randomised controlled feasibility study [J]. *Trials*, 2016, 17(1): 519. <https://doi.org/10.1186/s13063-016-1639-z>
- [99] Freed S. Acupuncture as therapy of traumatic affective disorders and of phantom limb pain syndrome [J]. *Acupunct Electrother Res*, 1989, 14(2): 121-129. <https://doi.org/10.3727/036012989816358452>
- [100] Tian H, Hu H, Li X, et al. Auricular therapy for treating phantom limb pain accompanied by jumping residual limb: a short review and case study [J]. *Pain Ther*, 2021, 10(1): 739-749. <https://doi.org/10.1007/s40122-021-00236-1>
- [101] Tseng CC, Chen PY, Lee YC. Successful treatment of phantom limb pain and phantom limb sensation in the traumatic amputee using scalp acupuncture [J]. *Acupunct Med*, 2014, 32(4): 356-358. <https://doi.org/10.1136/acupmed-2014-010556>
- [102] King H, Forrester M. Electroacupuncture for alleviation of phantom limb pain [J]. *J Rehabil Med Clin Commun*, 2021, 4: 1000063. <https://doi.org/10.2340/20030711-1000063>
- [103] Guo Q, Di Z, Tian HF, et al. Contralateral acupuncture for the treatment of phantom limb pain and phantom limb sensation in oncologic lower limb amputee: a case report [J]. *Front Neurosci*, 2021, 15: 713548. <https://doi.org/10.3389/fnins.2021.713548>
- [104] Zhao DW, Yao TS, Mu L, et al. Efficacy analysis of Meng Xianjie's self-prescribed formula for phantom limb pain after diabetic foot amputation [J]. *Clinical Journal of Traditional Chinese Medicine*, 2019, 31(2): 343-346. <https://doi.org/10.16448/j.cjtc.2019.0102>
- [105] Lin XG, Pan GQ. Clinical observation of 90 cases of Qi-stagnation and blood-stasis type phantom limb pain treated with Qi-activating and blood-circulating method [J]. *Journal of New Chinese Medicine*, 2014, 46(8): 78-80. <https://doi.org/10.13457/j.cnki.jncm.2014.08.036>
- [106] Ni HY, Zhang YM, Zhang XM. Treatment of post-traumatic amputation phantom limb pain primarily with Haitongpi Decoction fumigation therapy [J]. *The Journal of Traditional Chinese Orthopedics and Traumatology*, 2014, 26(8): 58-60.
- [107] McCormick ZL, Hendrix A, Dayanim D, et al. Lumbar sympathetic plexus block as a treatment for postamputation pain: methodology for a randomized controlled trial [J]. *Pain Med*, 2018, 19(12): 2496-2503. <https://doi.org/10.1093/pm/pny041>
- [108] Bornemann-Cimenti H, Dorn C, Rumpold-Seitlinger G. Early onset and treatment of phantom limb pain following surgical amputation [J]. *Pain Med*, 2017, 18(12): 2510-2512. <https://doi.org/10.1093/pm/pnx111>
- [109] Ilfeld BM, Moeller-Bertram T, Hanling SR, et al. Treating intractable phantom limb pain with ambulatory continuous peripheral nerve blocks: a pilot study [J]. *Pain Med*, 2013, 14(6): 935-942. <https://doi.org/10.1111/pme.12080>
- [110] Neil MJ. Brachial plexus block in phantom limb pain: interesting, but limited clinical benefit in chronic setting [J]. *Pain Med*, 2012, 13(6): 849. <https://doi.org/10.1111/j.1526-4637.2012.01370.x>
- [111] Sekiguchi S, Ishida Y, Fujita Y, et al. A case of phantom pain and stump pain that was effectively controlled by ultrasound-guided ulnar and median peripheral nerve blocks [J]. *Clin Case Rep*, 2023, 11(7): e7672. <https://doi.org/10.1002/ccr3.7672>
- [112] Warner NS, Warner MA, Moeschler SM, et al. Pain management in four-limb amputation: a case report [J]. *Pain Pract*, 2015, 15(7): E76-80. <https://doi.org/10.1111/papr.12307>
- [113] Ilfeld BM, Khatibi B, Maheshwari K, et al. Ambulatory continuous peripheral nerve blocks to treat postamputation phantom limb pain: a multicenter, randomized, quadruple-masked, placebo-controlled clinical trial [J]. *Pain*, 2021, 162(3): 938-955. <https://doi.org/10.1097/j.pain.0000000000002087>
- [114] Borghi B, D'Addabbo M, White PF, et al. The use of prolonged peripheral neural blockade after lower extremity amputation: the effect on symptoms associated with phantom limb syndrome [J]. *Anesth Analg*, 2010, 111(5): 1308-1315. <https://doi.org/10.1213/ANE.0b013e3181f4e848>
- [115] Makkar JK, Bandyopadhyay A, Jain K, et al. Effect of perioperative sciatic nerve block on chronic pain in patients undergoing below-knee amputation: A randomised controlled trial [J]. *Indian J Anaesth*, 2022, 66(Suppl 6): S300-S306. https://doi.org/10.4103/ija.ija_796_21
- [116] Zeng Y, Wang X, Guo Y, et al. Coblation of femoral and sciatic nerve for stump pain and phantom limb pain: a case report [J]. *Pain Pract*, 2016, 16(2): E35-41. <https://doi.org/10.1111/papr.12400>
- [117] Buch NS, Ahlburg P, Haroutounian S, et al. The role of afferent input in postamputation pain: a randomized, double-blind, placebo-controlled crossover study [J]. *Pain*, 2019, 160(7): 1622-1633. <https://doi.org/10.1097/j.pain.0000000000001536>
- [118] Grap SM, Fox E, Freeman M, et al. Acute postoperative pain management after major limb amputation in a pediatric patient: a case report [J]. *J Perianesth Nurs*, 2019, 34(4): 801-809. <https://doi.org/10.1016/j.jopan.2018.11.004>

- [119] Soin A, Shah NS, Fang ZP. High-frequency electrical nerve block for postamputation pain: a pilot study [J]. *Neuromodulation*, 2015, 18(3): 197-205; discussion 205-206. <https://doi.org/10.1111/ner.12266>
- [120] Ilfeld BM, Khatibi B, Maheshwari K, et al. Immediate effects of a continuous peripheral nerve block on postamputation phantom and residual limb pain: secondary outcomes from a multicenter randomized controlled clinical trial [J]. *Anesth Analg*, 2021, 133(4): 1019-1027. <https://doi.org/10.1213/ANE.0000000000005673>
- [121] Ilfeld BM, Khatibi B, Maheshwari K, et al. Patient-centered results from a multicenter study of continuous peripheral nerve blocks and postamputation phantom and residual limb pain: secondary outcomes from a randomized, clinical trial [J]. *Reg Anesth Pain Med*, 2023, 48(9): 471-477. <https://doi.org/10.1136/rapm-2023-104389>
- [122] Sperry BP, Cheney CW, Conger A, et al. Cooled radiofrequency ablation of a large sciatic neuroma at the infra-piriformis foramen for recalcitrant phantom limb pain in a below-knee amputee [J]. *Pain Med*, 2021, 22(1): 223-226. <https://doi.org/10.1093/pm/pnaa154>
- [123] Pu S, Wu J, Han Q, et al. Ultrasonography-guided radiofrequency ablation for painful stump neuromas to relieve post-amputation pain: a pilot study [J]. *J Pain Res*, 2020, 13: 3437-3445. <https://doi.org/10.2147/JPR.S283986>
- [124] Li H, Li Y, Guo Z, et al. Low-temperature plasma radiofrequency ablation in phantom limb pain: A case report [J]. *Brain Circ*, 2018, 4(2): 62-64. https://doi.org/10.4103/bc.bc_7_17
- [125] Brzeziński K, Rękas-Dudziak AR, Maruszczyńska A. Pulsed radiofrequency as alternative method for phantom pain treatment. Case report [J]. *Clin Case Rep*, 2020, 8(10): 2060-2062. <https://doi.org/10.1002/ccr3.3110>
- [126] Imani F, Gharaei H, Rezvani M. Pulsed radiofrequency of lumbar dorsal root ganglion for chronic postamputation phantom pain [J]. *Anesth Pain Med*, 2012, 1(3): 194-197. <https://doi.org/10.5812/kowsar.22287523.3768>
- [127] Srinivasan N, Zhou B, Park E. Dorsal root ganglion stimulation for the management of phantom limb pain: a scoping review [J]. *Pain Physician*, 2022, 25(8): E1174-E1182.
- [128] Wester K. Dorsal column stimulation in pain treatment [J]. *Acta Neurol Scand*, 1987, 75(2): 151-155. <https://doi.org/10.1111/j.1600-0404.1987.tb07910.x>
- [129] Song JJ, Popescu A, Bell RL. Present and potential use of spinal cord stimulation to control chronic pain [J]. *Pain Physician*, 2014, 17(3): 235-246.
- [130] Guan Y. Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action [J]. *Curr Pain Headache Rep*, 2012, 16(3): 217-225. <https://doi.org/10.1007/s11916-012-0260-4>
- [131] Broggi G, Servello D, Dones I, et al. Italian multicentric study on pain treatment with epidural spinal cord stimulation [J]. *Stereotact Funct Neurosurg*, 1994, 62(1-4): 273-278. <https://doi.org/10.1159/000098632>
- [132] Aiyyer R, Barkin RL, Bhatia A, et al. A systematic review on the treatment of phantom limb pain with spinal cord stimulation [J]. *Pain Manag*, 2017, 7(1): 59-69. <https://doi.org/10.2217/pmt-2016-0041>
- [133] Pereira EA, Boccard SG, Linhares P, et al. Thalamic deep brain stimulation for neuropathic pain after amputation or brachial plexus avulsion [J]. *Neurosurg Focus*, 2013, 35(3): E7. <https://doi.org/10.3171/2013.7.FOCUS1346>
- [134] Pet MA, Ko JH, Friedly JL, et al. Does targeted nerve implantation reduce neuroma pain in amputees? [J]. *Clin Orthop Relat Res*, 2014, 472(10): 2991-3001. <https://doi.org/10.1007/s11999-014-3602-1>
- [135] Dumanian GA, Potter BK, Mioton LM, et al. Targeted muscle reinnervation treats neuroma and phantom pain in major limb amputees: a randomized clinical trial [J]. *Ann Surg*, 2019, 270(2): 238-246. <https://doi.org/10.1097/SLA.0000000000003088>
- [136] Berger LE, Shin S, Haffner ZK, et al. The application of targeted muscle reinnervation in lower extremity amputations: a systematic review [J]. *Microsurgery*, 2023. <https://doi.org/10.1002/micr.31030>
- [137] Valerio IL, Dumanian GA, Jordan SW, et al. Preemptive treatment of phantom and residual limb pain with targeted muscle reinnervation at the time of major limb amputation [J]. *J Am Coll Surg*, 2019, 228(3): 217-226. <https://doi.org/10.1016/j.jamcollsurg.2018.12.015>
- [138] Antfolk C, D'Alonzo M, Rosén B, et al. Sensory feedback in upper limb prosthetics [J]. *Expert Rev Med Devices*, 2013, 10(1): 45-54. <https://doi.org/10.1586/erd.12.68>
- [139] Du T, Ji F, Ni B, et al. Factors affecting long-term outcome in dorsal root entry zone lesioning for brachial plexus avulsion [J]. *Pain*, 2023, 164(5): 977-983. <https://doi.org/10.1097/j.pain.0000000000002788>
- [140] Ilfeld BM, Smith CR, Turan A, et al. Ultrasound-guided percutaneous cryoneurolysis to treat chronic postamputation phantom limb pain: a multicenter randomized controlled trial [J]. *Anesthesiology*, 2023, 138(1): 82-97. <https://doi.org/10.1097/ALN.0000000000004429>
- [141] Biel E, Aroke EN, Maye J, et al. The applications of cryoneurolysis for acute and chronic pain management [J]. *Pain Pract*, 2023, 23(2): 204-215. <https://doi.org/10.1111/papr.13182>
- [142] Wakolbinger R, Diers M, Hruby LA, et al. Home-Based tactile discrimination training reduces phantom limb pain [J]. *Pain Pract*, 2018, 18(6): 709-715. <https://doi.org/10.1111/papr.12657>
- [143] Saleh Velez FG, Pinto CB, Bailin ES, et al. Real-time video projection in an MRI for characterization of neural correlates associated with mirror therapy for phantom limb pain [J]. *J Vis Exp*, 2019, (146): 10.3791/58800. <https://doi.org/10.3791/58800>
- [144] Moseley LG, Wiech K. The effect of tactile discrimination training is enhanced when patients watch the reflected image of their unaffected limb during training [J]. *Pain*, 2009, 144(3): 314-319. <https://doi.org/10.1016/j.pain.2009.04.030>

- [145] Durmus D, Safaz I, Adıgüzel E, et al. The relationship between prosthesis use, phantom pain and psychiatric symptoms in male traumatic limb amputees [J]. *Compr Psychiatry*, 2015, 59: 45-53. <https://doi.org/10.1016/j.comppsy.2014.10.018>